Acute cardiovascular alterations and post-COVID-19 syndrome
DOI:
https://doi.org/10.35954/SM2021.40.2.4.e401Keywords:
COVID-19; Cardiovascular Diseases; Heart Disease Risk Factors; Myocardium SARS-CoV-2; Troponin.Abstract
The SARS-CoV-2 virus disease, COVID-19, since its recognition in December 2019 until today has generated multiple challenges to the scientific community. Aspects of the virus, its transmission and pathogenesis are known but there are still elements that are under permanent review and challenge the adaptive capacity of the healthcare system. Most patients have mild symptoms, but a percentage evolve to severe respiratory failure called acute respiratory distress syndrome, which can culminate in septic or cardiogenic shock and death. Patients with underlying cardiovascular comorbidities, such as hypertension, diabetes and coronary artery disease, are more prone to severe coronavirus infection, which requires admission to intensive care units and is associated with increased mortality.
In addition, patients who have had the disease may have persistent symptoms that often require a particular and even multidisciplinary approach because of the impact they have on quality of life. The aim of this review is to provide available evidence on COVID-19 disease and its short- and long-term cardiovascular consequences, bearing in mind that our understanding of its impact is constantly evolving.
Received for review: June 2021
Accepted for publication: October 2021
Correspondence: 8 de Octubre 3060. C.P.11600. Montevideo, Uruguay. Tel: (+598) 24876666 int.1810 .
Contact e-mail: zulycortellezzi@gmail.com
Downloads
References
(1) Organización Mundial de la Salud. Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020. Disponible en: https://www.who.int/es/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Consulta 21/08/2021]
(2) Uruguay. Sistema Nacional de Emergencia SINAE. Visualizador de casos. Disponible en: https://www.gub.uy/sistema-nacional-emergencias/ [Consulta 21/08/2021]
(3) Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation 2020 May 19; 141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941
(4) Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5(7):811-8. doi:10.1001/jamacardio.2020.1017
(5) García L, Morell D, Rodríguez O, Morales C, Padilla P, Gutiérrez J, et al. Cardiac troponin and COVID-19 severity: Results from BIOCOVID study. Eur J Clin Invest 2021; 51:e13532. doi: 10.1111/eci.13532
(6) De Michieli L, Ola O, Knott J, Akula A, Mehta R, Hodge D, et al. High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19. J Am Coll Cardiol 2021 May 11; 77(18): 3145. doi: 10.1016/S0735-1097(21)04500-9
(7) Akhmerov A, Marbán E. COVID-19 and the Heart. Circulation Research 2020; 126(810):1443-1455. doi:10.1161/CIRCRESAHA.120.317055
(8) Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, et al. Takotsubo syndrome in the setting of COVID-19. JACC CaseRep. 2020; 2(9):1321–5. doi.org/10.1016/j.jaccas.2020.04.023
(9) Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev 2021 Mar 24; 1-11. doi: 10.1007/s10741-021-10087-9
(10) Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 2020; 3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619
(11) Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail.2020; 22(12):2238-2247. doi: 10.1002/ejhf.2052.
(12) Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94:91-5. doi: 10.1016/j.ijid.2020.03.017
(13) Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020 Apr 7; 323(13):1239-1242. doi: 10.1001/jama.2020.2648
(14) Costa I, Bittar CS, Rizk SI, Araujo Filho AE, Santos KAQ, Machado TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. Arq Bras Cardiol 2020; 114:805-816. doi: 10.36660/abc.20200279.
(15) Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020 Jul; 28(7):1195-1199. doi: 10.1002/oby.22831
(16) Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020 May 26; 323(20):2052-2059. doi: 10.1001/jama.2020.6775
(17) Vardavas CI, Nikitara K. COVID-19 and smoking: A system review of the evidence. Tob Induc Dis 2020 Mar 20; 18:20. doi: 10.18332/tid/119324. eCollection 2020.
(18) Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol 2020 May 12; 75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031
(19) Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation 2020; 141(23):1903-1914. doi:10.1161/CIRCULATIONAHA.120.047349
(20) Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory confirmed influenza infection. N Engl J Med 2018 Jan 25; 378(4):345-353. doi: 10.1056/NEJMoa1702090
(21) Jaffe AS, Cleland JGF, Katus HA. Myocardial injury in severe COVID-19 infection. Eur Heart J 2020; 41(22):2080-2082. doi: 10.1093/eurheartj/ehaa447
(22) Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci 2020 Apr 10; 5(5):518-536. doi: 10.1016/j.jacbts.2020.04.002
(23) Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARSCoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol 2020; 5(11):1281-1285. doi:10.1001/jamacardio.2020.3551
(24) Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, VanderHeide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020; 8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5
(25) Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome. Circulation 2021; 143(6):553-565. doi:10.1161/CIRCULATIONAHA.120.050543
(26) Bois MC, Boire NA, Layman AJ, Aubry MC, Alexander MP, Roden AC, et al. COVID-19 associated non occlusive fibrin microthrombi in the heart. Circulation 2021; 143(3):230-243.doi:10.1161/CIRCULATIONAHA.120.050754
(27) Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail 2020; 8:512-4. https://doi.org/10.1016/j.jchf.2020.03.004
(28) Mueller C, McDonald K, Boer R, Maisel A, Cleland J, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019 Jun; 21(6):715-731. doi: 10.1002/ejhf.1494
(29) Lazzerini P, Boutjdir M, Capecchi P. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation 2020 Jul 7; 142(1):7-9. doi: 10.1161/CIRCULATIONAHA.120.047293
(30) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol 2020; 5(7):802-810. doi.org/10.1001/jamacardio.2020.0950
(31) Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, CanaleC, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: Results of a Multicenter Study. JAMA Cardiol 2020; 5(11):1274-1280. doi:10.1001/jamacardio.2020.3538
(32) Smilowitz NR, Jethani N, Chen J, Aphinyanaphongs Y, Zhang R, Dogra S, et al. Myocardial injury in adults hospitalized withCOVID-19. Circulation. 2020; 142 (24):2393-2395. doi:10.1161/CIRCULATIONAHA.120.050434
(33) Abate SM, Mantefardo B, Nega S, Chekole YA, Basu B, Ali SA, et al. Global burden of acute myocardial injury associated with COVID-19: A systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond) 2021; 68:102594. doi: 10.1016/j.amsu.2021.102594
(34) Calvo-Fernández A, Izquierdo A, Subirana I, Farré N, Vila J, Durán X, et al. Markers of myocardial injury in the prediction of short-term COVID-19 prognosis. Rev Esp Cardiol (Engl Ed) 2020; 74(7):576-583. doi: 10.1016/j.rec.2020.09.011
(35) Bikdeli B, Madhavan M, Jimenez D, ChuichT, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol 2020 Jun 16; 75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031
(36) Goerlich E, Minhas AS, Mukherjee M, Sheikh FH, Gilotra NA, Sharma G, et al. Multimodality imaging for cardiac evaluation inpatients with COVID-19. Curr Cardiol Rep 2021; 23(5):44. doi: 10.1007/s11886-021-01483-6
(37) Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (sars) and middle east respiratory syndrome (mers) coronavirus outbreaks after hospitalisation or icu admission: a systematic review and meta-analysis. J Rehabil Med 2020 May 31; 52(5):jrm00063. doi: 10.2340/16501977-2694
(38) Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020 Aug 11; 324(6):603-605. doi: 10.1001/jama.2020.12603
(39) Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. E Clinical Medicine 2021; 38:101019. doi: 10.1016/j.eclinm.2021.101019
(40) COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline. https://www.nice.org.uk/guidance/ng188
(41) World Health Organization. Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021. [on line] 36 p. Available from: https://www.who.int/publications/i/item/9789240025035 [Consulted 20/08/2021]
(42) Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance Available from: www.cdc.gov/coronavirus/2019- ncov/hcp/clinical-care/post-covid- conditions [Consulted 20/08/2021]
(43) Guía clínica para la atención del paciente Long Covid/Covid Persistente.[en línea] 118 p. Disponible en: https://www.semg.es/images/2021/Documentos/GUIA_CLINICA_COVID_Persistent_20210501_version_final.pdf [Consulta 26/08/2021]
(44) Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19 (GCMSC). Post-Acute COVID Syndrome (PACS): Definition, Impact and Management.[on line] 52 p. Available from: https://www.isglobal.org/documents/10179/7860911/Report+Post-Acute+COVID+Syndrome/58bf2369-c977-4c0a-8fbf-054f2d8df719 [Consulted 29/08/2021]
(45) Uruguay. Sociedad de Medicina Interna del Uruguay. Síndrome post-COVID-19: pautas de diagnóstico y tratamiento.[Sitio web] 56 p. Disponible en: https://www.medicinainterna.org.uy/wp-content/uploads/2021/08/SIND-POST-COVID19-SMIU.pdf [Consulta 30/08/2021]
(46) Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021 Apr; 27(4):601-615. doi: 10.1038/s41591-021-01283-z
(47) Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ 2021 Jul 26; 374:n1648. doi: 10.1136/bmj.n1648. Erratum in: BMJ 2021 Aug 3;374:n1944
(48) Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020 Nov; 17(11):1984-1990. doi: 10.1016/j.hrthm.2020.06.026
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
